Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Gross Profit: 2018-2023

Historic Gross Profit for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to $1.3 million.

  • Denali Therapeutics' Gross Profit fell 64.40% to $1.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $340.8 million, marking a year-over-year increase of 207.89%. This contributed to the annual value of $330.5 million for FY2023, which is 204.74% up from last year.
  • Latest data reveals that Denali Therapeutics reported Gross Profit of $1.3 million as of Q3 2023, which was down 99.57% from $294.1 million recorded in Q2 2023.
  • Denali Therapeutics' 5-year Gross Profit high stood at $316.8 million for Q4 2020, and its period low was $1.3 million during Q3 2023.
  • Its 3-year average for Gross Profit is $43.6 million, with a median of $12.5 million in 2021.
  • Its Gross Profit has fluctuated over the past 5 years, first slumped by 96.28% in 2019, then skyrocketed by 6,681.14% in 2020.
  • Denali Therapeutics' Gross Profit (Quarterly) stood at $4.7 million in 2019, then surged by 6,681.14% to $316.8 million in 2020, then slumped by 96.05% to $12.5 million in 2021, then declined by 17.83% to $10.3 million in 2022, then crashed by 64.40% to $1.3 million in 2023.
  • Its last three reported values are $1.3 million in Q3 2023, $294.1 million for Q2 2023, and $35.1 million during Q1 2023.